Are apolipoproteins A and B better than lipoproteins for assessing risk of obstructive coronary heart disease?
Autor(a) principal: | |
---|---|
Data de Publicação: | 1999 |
Outros Autores: | , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Arquivos Brasileiros de Cardiologia (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X1999000600001 |
Resumo: | OBJECTIVE: To evaluate whether apolipoproteins A-I (Apo A-I) and B (Apo B) have, higher ensitivity (SN), specificity (SP) and positive predictive value (PPV) than lipoproteins (LP), total cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein (LDL), very low density lipoprotein (VLDL), and triglycerides (TGL) in assessing the risk of coronary heart disease (CHD). METHODS: This is a transversal case-control study of 241 patients, who were divided into two groups: 1) 145 patients with CHD, and 2) 96 patients without coronary disease. A model of logistic regression to evaluate the relation between the LPs and CHD was developed in which variables with a p-alpha <0.1 were included. RESULTS: Apo A-I levels were higher in the patients without CHD, (OR 2.08, CI 1.20-3.57). There were no statistical differences between the values of Apo A-I and the remaining lipid fractions (Apo A-I: 67%; Apo B: 100%; PPV: TC= 71%; TGC=71%; HDL=71%; LDL=71%). The costs of the tests in Reais were as follows: Apo A-I: R$ 56.60; Apo B-100: R$ 56.60; TC: R$ 9.94; HDL: R$ 21.30; LDL: R$ 28.40; TGL: R$ 14.20. CONCLUSION: Levels of Apo A-I and Apo B have no advantage over conventional lipoproteins in predicting the risk of CHD, despite the statistical association between Apo A-I and CHD; in addition, their costs are higher than those of the conventional lipoproteins. |
id |
SBC-1_2d430dd6db83cfa9a2d12c61b1ecc24f |
---|---|
oai_identifier_str |
oai:scielo:S0066-782X1999000600001 |
network_acronym_str |
SBC-1 |
network_name_str |
Arquivos Brasileiros de Cardiologia (Online) |
repository_id_str |
|
spelling |
Are apolipoproteins A and B better than lipoproteins for assessing risk of obstructive coronary heart disease?risk factorscoronary heart diseaselipoproteinsOBJECTIVE: To evaluate whether apolipoproteins A-I (Apo A-I) and B (Apo B) have, higher ensitivity (SN), specificity (SP) and positive predictive value (PPV) than lipoproteins (LP), total cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein (LDL), very low density lipoprotein (VLDL), and triglycerides (TGL) in assessing the risk of coronary heart disease (CHD). METHODS: This is a transversal case-control study of 241 patients, who were divided into two groups: 1) 145 patients with CHD, and 2) 96 patients without coronary disease. A model of logistic regression to evaluate the relation between the LPs and CHD was developed in which variables with a p-alpha <0.1 were included. RESULTS: Apo A-I levels were higher in the patients without CHD, (OR 2.08, CI 1.20-3.57). There were no statistical differences between the values of Apo A-I and the remaining lipid fractions (Apo A-I: 67%; Apo B: 100%; PPV: TC= 71%; TGC=71%; HDL=71%; LDL=71%). The costs of the tests in Reais were as follows: Apo A-I: R$ 56.60; Apo B-100: R$ 56.60; TC: R$ 9.94; HDL: R$ 21.30; LDL: R$ 28.40; TGL: R$ 14.20. CONCLUSION: Levels of Apo A-I and Apo B have no advantage over conventional lipoproteins in predicting the risk of CHD, despite the statistical association between Apo A-I and CHD; in addition, their costs are higher than those of the conventional lipoproteins.Sociedade Brasileira de Cardiologia - SBC1999-06-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X1999000600001Arquivos Brasileiros de Cardiologia v.72 n.6 1999reponame:Arquivos Brasileiros de Cardiologia (Online)instname:Sociedade Brasileira de Cardiologia (SBC)instacron:SBC10.1590/S0066-782X1999000600001info:eu-repo/semantics/openAccessManfroi,Waldomiro CarlosZago,Alcides JoséCampos,MarceloAlves,AlexandreBrisolara,Maria LúciaSouza,Josiane deCandiago,Rafael HenriquesKirschnick,LucianaRibeiro,LetíciaOrdovás,KáremLeitão,CristianeCruz,Rosanaeng2002-01-08T00:00:00Zoai:scielo:S0066-782X1999000600001Revistahttp://www.arquivosonline.com.br/https://old.scielo.br/oai/scielo-oai.php||arquivos@cardiol.br1678-41700066-782Xopendoar:2002-01-08T00:00Arquivos Brasileiros de Cardiologia (Online) - Sociedade Brasileira de Cardiologia (SBC)false |
dc.title.none.fl_str_mv |
Are apolipoproteins A and B better than lipoproteins for assessing risk of obstructive coronary heart disease? |
title |
Are apolipoproteins A and B better than lipoproteins for assessing risk of obstructive coronary heart disease? |
spellingShingle |
Are apolipoproteins A and B better than lipoproteins for assessing risk of obstructive coronary heart disease? Manfroi,Waldomiro Carlos risk factors coronary heart disease lipoproteins |
title_short |
Are apolipoproteins A and B better than lipoproteins for assessing risk of obstructive coronary heart disease? |
title_full |
Are apolipoproteins A and B better than lipoproteins for assessing risk of obstructive coronary heart disease? |
title_fullStr |
Are apolipoproteins A and B better than lipoproteins for assessing risk of obstructive coronary heart disease? |
title_full_unstemmed |
Are apolipoproteins A and B better than lipoproteins for assessing risk of obstructive coronary heart disease? |
title_sort |
Are apolipoproteins A and B better than lipoproteins for assessing risk of obstructive coronary heart disease? |
author |
Manfroi,Waldomiro Carlos |
author_facet |
Manfroi,Waldomiro Carlos Zago,Alcides José Campos,Marcelo Alves,Alexandre Brisolara,Maria Lúcia Souza,Josiane de Candiago,Rafael Henriques Kirschnick,Luciana Ribeiro,Letícia Ordovás,Kárem Leitão,Cristiane Cruz,Rosana |
author_role |
author |
author2 |
Zago,Alcides José Campos,Marcelo Alves,Alexandre Brisolara,Maria Lúcia Souza,Josiane de Candiago,Rafael Henriques Kirschnick,Luciana Ribeiro,Letícia Ordovás,Kárem Leitão,Cristiane Cruz,Rosana |
author2_role |
author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Manfroi,Waldomiro Carlos Zago,Alcides José Campos,Marcelo Alves,Alexandre Brisolara,Maria Lúcia Souza,Josiane de Candiago,Rafael Henriques Kirschnick,Luciana Ribeiro,Letícia Ordovás,Kárem Leitão,Cristiane Cruz,Rosana |
dc.subject.por.fl_str_mv |
risk factors coronary heart disease lipoproteins |
topic |
risk factors coronary heart disease lipoproteins |
description |
OBJECTIVE: To evaluate whether apolipoproteins A-I (Apo A-I) and B (Apo B) have, higher ensitivity (SN), specificity (SP) and positive predictive value (PPV) than lipoproteins (LP), total cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein (LDL), very low density lipoprotein (VLDL), and triglycerides (TGL) in assessing the risk of coronary heart disease (CHD). METHODS: This is a transversal case-control study of 241 patients, who were divided into two groups: 1) 145 patients with CHD, and 2) 96 patients without coronary disease. A model of logistic regression to evaluate the relation between the LPs and CHD was developed in which variables with a p-alpha <0.1 were included. RESULTS: Apo A-I levels were higher in the patients without CHD, (OR 2.08, CI 1.20-3.57). There were no statistical differences between the values of Apo A-I and the remaining lipid fractions (Apo A-I: 67%; Apo B: 100%; PPV: TC= 71%; TGC=71%; HDL=71%; LDL=71%). The costs of the tests in Reais were as follows: Apo A-I: R$ 56.60; Apo B-100: R$ 56.60; TC: R$ 9.94; HDL: R$ 21.30; LDL: R$ 28.40; TGL: R$ 14.20. CONCLUSION: Levels of Apo A-I and Apo B have no advantage over conventional lipoproteins in predicting the risk of CHD, despite the statistical association between Apo A-I and CHD; in addition, their costs are higher than those of the conventional lipoproteins. |
publishDate |
1999 |
dc.date.none.fl_str_mv |
1999-06-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X1999000600001 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X1999000600001 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/S0066-782X1999000600001 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Cardiologia - SBC |
publisher.none.fl_str_mv |
Sociedade Brasileira de Cardiologia - SBC |
dc.source.none.fl_str_mv |
Arquivos Brasileiros de Cardiologia v.72 n.6 1999 reponame:Arquivos Brasileiros de Cardiologia (Online) instname:Sociedade Brasileira de Cardiologia (SBC) instacron:SBC |
instname_str |
Sociedade Brasileira de Cardiologia (SBC) |
instacron_str |
SBC |
institution |
SBC |
reponame_str |
Arquivos Brasileiros de Cardiologia (Online) |
collection |
Arquivos Brasileiros de Cardiologia (Online) |
repository.name.fl_str_mv |
Arquivos Brasileiros de Cardiologia (Online) - Sociedade Brasileira de Cardiologia (SBC) |
repository.mail.fl_str_mv |
||arquivos@cardiol.br |
_version_ |
1752126550899163136 |